ATXA to Attend and Present at the Pulmonary Vascular Research Institute 2026 Annual Congress

ATXA Therapeutics is looking forward to attending and presenting at the Pulmonary Vascular Research Institute (PVRI) Annual Congress 2026, taking place in Dublin, Ireland, from January 28 to February 1, 2026.

The PVRI Annual Congress is a uniquely cross-disciplinary forum that brings together clinicians, translational scientists, and industry leaders to share late-breaking insights and accelerate progress for patients across the pulmonary hypertension (PH) spectrum. This year’s event is particularly significant, marking the 20th anniversary of the meeting.

At PVRI 2026, ATXA will present data strengthening the evidence for the involvement of its drug target, the thromboxane receptor (TP), in a range of cardiopulmonary diseases. These data highlight the therapeutic potential of ATXA’s TP antagonist clinical candidate, NTP42, as a novel strategy to address the underlying pulmonary and cardiac dysfunction.

Title: Expression of the Human Thromboxane Receptor in Pulmonary Hypertension and Related Cardiopulmonary Diseases

Date/Time/Venue: Thursday, January 29, 2026, 3:45 – 5:00 p.m. GMT, Higgins Room

Paper Number: 19

In a presentation entitled “Expression of the Human Thromboxane Receptor in Pulmonary Hypertension and Related Cardiopulmonary Diseases”, ATXA will report on the findings of widespread TP expression in remodelled vasculature and other disease-associated cell types in lungs from patients with pulmonary arterial hypertension (PAH) and Group 3 PH, including PH associated with idiopathic pulmonary fibrosis (iPF). Elevated TP expression was also observed in the right ventricle (RV) in PAH, with similar findings in cardiac tissue from patients with dilated cardiomyopathy (DCM), a key driver of Group 2 PH associated with left heart failure (HF). Importantly, these observations in clinical tissue are supported by bioinformatic analyses of publicly available genomic datasets and are also consistent with findings from ATXA’s preclinical studies, which demonstrate robust increases in TP expression across lung and heart tissues in translational models of PH and HF.

Following the presentation, a copy of the poster will be made available in the “Our Publications” section of ATXA’s website at atxatherapeutics.com.